智通财经APP获悉，昭衍新药(06127)大跌逾16%，截至发稿，跌16.27%，报9.88港元，成交额8732.91万港元。
消息面上，据报道，美国食品药品管理局（FDA）宣称，将在单抗等诸多药物方面逐步放弃动物试验路线，转而追求“更有效的人类相关研究方法”。据悉，昭衍新药2024年实现收入20.2亿元，同比下降15%，公司权益股东应占年内溢利7407.5万元，同比减少81.3%。根据24年报披露，其24年实验室业务贡献0.5亿元、资产管理收益贡献0.9 亿元、生物资产公允价值变动为-1.1亿元，整体体现实验室贡献利润相对23年的4.7亿元显著下降。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.